P210: Comprehensive Analysis of Pharmacovigilance Inspection Practices in the Pharmaceutical Industry in Saudi Arabia
Poster Presenter
Malak Almutairi
Researcher
Saudi Food and Drug Authority Saudi Arabia
Objectives
This study aimed to comprehensively analyze inspection findings among North American and European MAHs, Gulf and North African MAHs, and Saudi Arabian MAHs and highlight areas of concern within the inspection topics of MAHs in Saudi Arabia.
Method
descriptive secondary data analysis was performed to examine inspection reports from the SFDA between January 2019 and December 2022. The MAHs were categorized into three groups according to their countries of origin: North American and European , Gulf and North African , and Saudi Arabian MAHs
Results
The study analyzed 1122 inspection findings from 2019 to 2022, categorized based on severity and MAH type. North American MAHs had the highest number of findings [498, (46.7%)], with Major findings being the highest proportion in all [704, (62.7%)] MAH types. Additionally, management and signal management consistently emerged as a top inspection topic.
Conclusion
The analysis of MAHs and their inspection findings between 2019 and 2022 has revealed that North American and European MAHs consistently reported higher inspection findings than Gulf and North African and Saudi Arabian MAHs. More inspection findings in Gulf and North African MAHs than in Saudi Arabian MAHs highlight the impact of regional guidelines, regulatory interpretations, resource constraints, and communication challenges on inspection outcomes. The lack of harmonization in pharmacovigilance systems between Saudi Arabia and neighboring countries further might contributed to major findings, emphasizing the need for alignment with global pharmacovigilance standards. Moreover, areas for improvement were identified, such as management and reporting adverse reactions.
